{
 "as_of": "2026-11-06",
 "cmr": "dk-cm-kg/XCSE/DK0060257814",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Zealand Pharma A/S (Nasdaq Copenhagen: DK0060257814) — research page\n\nAs of 2026-11-06 · dk-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Zealand Pharma A/S, listed on Nasdaq Copenhagen under ticker DK0060257814, with ISIN DK0060257814 and LEI 549300ITBB1ULBL4CZ12. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 59 filings across 49 filing days in the window from 2025-11-06 to 2026-11-06. The median gap between filing days is 6.0 days. The latest filing is dated 2026-10-07, 30 days before the record date of 2026-11-06, and is of type Inside information. The exchange median cadence gap is 8.0 days, the exchange median filings count is 25, and the exchange median latency is 4.0 days across 119 issuers. The sector median is not on the record.\n\n## Auditor\n\nThe auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is not set, and the issuer is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories to name. The rule version is acm-68000/dk/mifid-ii-product-governance/r1, with the chapter as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations pages read.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.\n\n## Sources\n\n6 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.dk-cm-kg.ai/events/XCSE/DK0060257814 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH (the halt flag)\n- https://dk.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.dk-cm-kg.ai/record/XCSE/DK0060257814 (the record)\n",
 "market": "DK",
 "node": "dk-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the DK vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "DK",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "DK",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "DK",
    "state": "not_on_record"
   },
   "changes": {
    "market": "DK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "dk-cm-kg/XCSE/DK0060257814",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [
    {
     "page": "https://www.zealandpharma.com/investors/analyst-coverage/",
     "result": "not readable by this rail (403)"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 119,
     "median_cadence_gap_days": 8,
     "median_filings": 25,
     "median_latency_days": 4,
     "name": "Nasdaq Copenhagen"
    },
    "sector": {
     "market": "DK",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual Financial Report": 1,
    "Changes in company's own shares": 24,
    "Decisions of general meeting": 2,
    "Half Year financial report": 1,
    "Inside information": 8,
    "Interim report (Q1 and Q3)": 2,
    "Major shareholder announcements": 1,
    "Managers' Transactions": 9,
    "Notice to general meeting": 2,
    "Other information disclosed according to the rules of the Exchange": 1,
    "Total number of voting rights and capital": 8
   },
   "cadence_median_gap_days": 6,
   "filing_days": 49,
   "filings": 59,
   "latency_days": 30,
   "latest": [
    {
     "category": "Inside information",
     "date": "2026-10-07",
     "source": "https://view.news.eu.nasdaq.com/view?id=bc1e6ac809532b09824e1a5f7f43ca6bf&lang=en&src=listed",
     "title": "Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes",
     "type": "Inside information"
    },
    {
     "category": "Changes in company's own shares",
     "date": "2026-10-05",
     "source": "https://view.news.eu.nasdaq.com/view?id=b1acbfef957be6d93c90b964cda960281&lang=en&src=listed",
     "title": "Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026)",
     "type": "Changes in company's own shares"
    },
    {
     "category": "Inside information",
     "date": "2026-10-01",
     "source": "https://view.news.eu.nasdaq.com/view?id=b8b75be02f58d976dc0629f0beaf1b9b3&lang=en&src=listed",
     "title": "Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes",
     "type": "Inside information"
    },
    {
     "category": "Total number of voting rights and capital",
     "date": "2026-09-30",
     "source": "https://view.news.eu.nasdaq.com/view?id=bd461ac4e44c1ee9d1242b7e1d547ea96&lang=en&src=listed",
     "title": "Total number of shares and voting rights in Zealand Pharma as of September 30, 2026",
     "type": "Total number of voting rights and capital"
    },
    {
     "category": "Changes in company's own shares",
     "date": "2026-09-28",
     "source": "https://view.news.eu.nasdaq.com/view?id=b5a970c712f8bfc87b874486e10e505b2&lang=en&src=listed",
     "title": "Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)",
     "type": "Changes in company's own shares"
    }
   ],
   "latest_filing_date": "2026-10-07",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.dk-cm-kg.ai/events/XCSE/DK0060257814",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/dk roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Nasdaq Copenhagen"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/dk roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "DK0060257814"
   },
   "jurisdiction": {
    "market": "DK",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN DK0060257814)",
    "state": "sourced",
    "value": "549300ITBB1ULBL4CZ12"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/dk roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Zealand Pharma A/S"
   },
   "sector": {
    "market": "DK",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "DK",
    "state": "not_on_record"
   },
   "segment": {
    "market": "DK",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/dk roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "DK0060257814"
   },
   "website": {
    "market": "DK",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "DK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "DK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "DK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "DK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "DK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "DK",
  "node": "dk-cm-kg",
  "numbers_hash": "sha256:41075b7e4e515c5c9b6c94e140287bc608a52ae79739299c842cb6c1f41639c6",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://dk.eu-cm-kg.ai/book/aio.json",
    "door": "https://dk.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/dk/mifid-ii-product-governance/r1",
   "section": "dk.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.dk-cm-kg.ai/record/XCSE/DK0060257814",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:41075b7e4e515c5c9b6c94e140287bc608a52ae79739299c842cb6c1f41639c6",
 "path": "/dk/XCSE/DK0060257814",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Zealand Pharma A/S, listed on Nasdaq Copenhagen under ticker DK0060257814, with ISIN DK0060257814 and LEI 549300ITBB1ULBL4CZ12. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 59 filings across 49 filing days in the window from 2025-11-06 to 2026-11-06. The median gap between filing days is 6.0 days. The latest filing is dated 2026-10-07, 30 days before the record date of 2026-11-06, and is of type Inside information. The exchange median cadence gap is 8.0 days, the exchange median filings count is 25, and the exchange median latency is 4.0 days across 119 issuers. The sector median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is not set, and the issuer is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories to name. The rule version is acm-68000/dk/mifid-ii-product-governance/r1, with the chapter as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's investor-relations pages read.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "6 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.dk-cm-kg.ai/events/XCSE/DK0060257814"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH"
  },
  {
   "for": "the orderability chapter",
   "source": "https://dk.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.dk-cm-kg.ai/record/XCSE/DK0060257814"
  }
 ],
 "title": "Zealand Pharma A/S (DK0060257814) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}